Novavax, Inc.

NASDAQ:NVAX

13.85 (USD) • At close July 19, 2024
Bedrijfsnaam Novavax, Inc.
Symbool NVAX
Munteenheid USD
Prijs 13.85
Beurswaarde 1,944,595,400
Dividendpercentage 0%
52-weken bereik 3.53 - 23.86
Industrie Biotechnology
Sector Healthcare
CEO Mr. John Charles Jacobs M.B.A.
Website https://www.novavax.com

An error occurred while fetching data.

Over Novavax, Inc.

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu,

Vergelijkbare Aandelen

Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc.

ARWR

28.3 USD

Surgery Partners, Inc. logo

Surgery Partners, Inc.

SGRY

29.05 USD

LivaNova PLC logo

LivaNova PLC

LIVN

52.91 USD

Guardant Health, Inc. logo

Guardant Health, Inc.

GH

30.75 USD

Natera, Inc. logo

Natera, Inc.

NTRA

105.98 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

85.49 USD

Amedisys, Inc. logo

Amedisys, Inc.

AMED

97.6 USD

Cerevel Therapeutics Holdings, Inc. logo

Cerevel Therapeutics Holdings, Inc.

CERE

42.9 USD

CureVac N.V. logo

CureVac N.V.

CVAC

3.67 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)